deferasirox has been researched along with Hemarthrosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coeleveld, K; Lafeber, FPJG; Mastbergen, SC; Pulles, AE; Schutgens, REG; van Vulpen, LFD | 1 |
| Biesma, DH; Coeleveld, K; Lafeber, FP; Mastbergen, SC; Nieuwenhuizen, L; Roosendaal, G; Schutgens, RE | 1 |
2 other study(ies) available for deferasirox and Hemarthrosis
| Article | Year |
|---|---|
On-demand treatment with the iron chelator deferasirox is ineffective in preventing blood-induced joint damage in haemophilic mice.
Topics: Animals; Cartilage, Articular; Deferasirox; Hemarthrosis; Hemophilia A; Iron Chelating Agents; Mice | 2021 |
Deferasirox limits cartilage damage following haemarthrosis in haemophilic mice.
Topics: Animals; Benzoates; Cartilage, Articular; Chelation Therapy; Deferasirox; Drug Evaluation, Preclinical; Ferritins; Hemarthrosis; Hemophilia A; Iron Chelating Agents; Mice; Mice, Mutant Strains; Random Allocation; Synovitis; Triazoles | 2014 |